SKYRIZI 150 mg SOLUCION INYECTABLE EN JERINGA PRECARGADA

( ARTG ) Psoriasis SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy. Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to or are into​​​‍​​‍​​​​‍​​‍‍lerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). SKYRIZI may be used with or without conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Crohns Disease SKYRIZI is indicated for the treatment of moderate to severe Crohns disease in adult patients, who have an inadequate response, a lost response, an intolerance or a contra-indication to either conventional or biologic therapy. Ulcerative Colitis SKYRIZI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or biologic therapy.